Literature DB >> 11982719

Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants.

Kunio Okuda1.   

Abstract

The natural history of hepatocellular carcinoma (HCC) varies greatly with the global region, because the carcinogenic factors are not the same among countries. Besides the clinicopathological factors such as tumor characteristics, sex, and age, background liver disease is a major determinant of prognosis. Hepatocellular carcinoma, mainly associated with chemical carcinogens such as aflatoxin, does not have severe background cirrhosis, and grows quickly, whereas HCC developing in association with a virus in a cirrhotic liver generally grows more slowly, and the severity of cirrhosis is the major prognostic factor. The median survival of untreated sub-Saharan African patients is less than 1 month from diagnosis, contrasted by an average survival of 4 months in virus-induced HCC associated with cirrhosis. Tumor characteristics, such as size, number, and growth speed, which vary considerably from case to case, affect the prognosis. Vascular (portal) invasion portends a poor prognosis, and alpha-fetoprotein levels also correlate with prognosis. Several distinct clinical types of HCC occur, namely diffuse-type HCC caused by rapid portal spread of cancer cells, febrile-type caused by poorly differentiated sarcomatoid cancer cells, and cholestatic HCC caused by intraductal invasion; all have a short survival. There are several histological variant forms: combined hepato-cholangiocarcinoma behaves like HCC, with a poorer prognosis because of more frequent lymph node metastases; fibromellar carcinoma, which is relatively common in young Caucasian adults, has a good prognosis if diagnosed early, permitting resection; and cholangiolocellular carcinoma, which derives from the canalicular epithelium, is indistinguishable from HCC, with a similar prognosis. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2002        PMID: 11982719     DOI: 10.1046/j.1440-1746.2002.02734.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  33 in total

Review 1.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

2.  Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.

Authors:  Imane El Dika; Anita S Bowman; Michael F Berger; Marinela Capanu; Joanne F Chou; Ryma Benayed; Ahmet Zehir; Jinru Shia; Eileen M O'Reilly; David S Klimstra; David B Solit; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2020-07-14       Impact factor: 6.860

3.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells.

Authors:  Shao-wu Zou; Kai-xing Ai; Zhi-gang Wang; Zhou Yuan; Jun Yan; Qi Zheng
Journal:  Acta Pharmacol Sin       Date:  2011-03       Impact factor: 6.150

5.  Imaging findings and transcatheter arterial chemoembolization of hepatic malignancy with right atrial embolus in 46 patients.

Authors:  Hong-Yan Cheng; Xiao-Yan Wang; Guo-Li Zhao; Dong Chen
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 6.  Radiofrequency ablation of cancer.

Authors:  Marc Friedman; Igor Mikityansky; Anthony Kam; Steven K Libutti; McClellan M Walther; Ziv Neeman; Julia K Locklin; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2004-06-03       Impact factor: 2.740

7.  Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization probes.

Authors:  Xiangdong David Ren; Selena Y Lin; Xiaohe Wang; Tianlun Zhou; Timothy M Block; Ying-Hsiu Su
Journal:  J Virol Methods       Date:  2009-01-31       Impact factor: 2.014

8.  Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma.

Authors:  Keh M Ng; Tristan D Yan; Deborah Black; Francis C K Chu; David L Morris
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

9.  Hepatitis C virus core protein augments androgen receptor-mediated signaling.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

10.  Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.

Authors:  Tobias Eggert; Katherine A McGlynn; Austin Duffy; Michael Peter Manns; Tim F Greten; Sean F Altekruse
Journal:  Gut       Date:  2013-05-25       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.